Paolo Tombesi - 26 Jul 2021 Form 4 Insider Report for Turning Point Therapeutics, Inc.

Role: EVP & Chief Financial Officer
Signature: /s/ Annette North, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 26 Jul 2021
Net transactions value: $0
Form type: 4
Filing time: 27 Jul 2021, 18:22:14 UTC
Next filing: 11 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TPTX	Common Stock	Award	$0	+13,600		$0.000000	13,600	26 Jul 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TPTX	Stock Option (right to buy)	Award	$0	+61,200		$0.000000	61,200	26 Jul 2021	Common Stock	61,200	$62.63	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock unit award granted under the Issuer's 2019 Equity Incentive Plan.
F2	25% of the shares vest on July 26, 2022 and 1/48th of the shares vest monthly thereafter over the next three years.